GO
Loading...

Novartis AG

More

  • Robust earnings help Europe stocks resume rally Tuesday, 28 Oct 2014 | 5:35 AM ET

    *FTSEurofirst 300 up 0.8 pct, Euro STOXX 50 up 0.9 pct. *Sanofi share drop represents $10 bln market value wipeout. PARIS, Oct 28- European shares rose in early trade on Tuesday, reversing the previous session's dip as better-than-expected results from a number of blue-chips including pharma group Novartis and bank UBS helped lift sentiment.

  • European shares rise early; Sanofi sinks Tuesday, 28 Oct 2014 | 4:08 AM ET

    PARIS, Oct 28- European shares rose in early trade on Tuesday, reversing the previous session's dip as better-than-expected results from a number of blue-chips including pharma group Novartis and bank UBS helped lift sentiment. At 0803 GMT, the FTSEurofirst 300 index of top European shares was up 0.6 percent at 1,313.05 points, with UBS up 1.9 percent and...

  • LONDON, Oct 27- Drugmakers sprinting to develop Ebola vaccines face a series of technical hurdles if they are to get millions of doses ready for use next year-- even assuming clinical trials are successful. The challenges include finding sufficient sterile capacity for filling and packaging finished vials, getting fast quality approvals from regulators, and...

  • Drugmakers double down on Ebola vaccines, treatments Monday, 27 Oct 2014 | 7:31 AM ET
    People participate in a march, organized by New York’s West African community, to end Ebola, Oct. 24, 2014, in New York.

    Drugmakers are racing to develop vaccines and drugs to address Ebola, betting that governments and aid groups will foot the bill.

  • *Exploring IPO of minority stake in ViiV Healthcare. LONDON, Oct 22- GlaxoSmithKline, battered by weak U.S. drug sales and a bribery scandal in China, is looking to float its fast-growing HIV drugs business as part of a recovery plan that includes a fresh round of cost cutting. As a standalone company ViiV Healthcare would be among the top 40 companies in London's...

  • *Exploring IPO of minority stake in ViiV Healthcare. LONDON, Oct 22- GlaxoSmithKline, battered by weak U.S. drug sales and a bribery scandal in China, set out a bold recovery plan on Wednesday, including an initial public offering of part of its fast-growing HIV and AIDS drugs business. As a standalone company ViiV Healthcare would be among the top 40 companies in...

  • "Building 1" is already under construction in Basel and at a height of 178 metres will become the country's tallest building when it opens at the end of 2015.. The drugmaker traces its roots in Basel to 1896 when Fritz Hoffman-La Roche set up the business, and it is now one of the world's most successful pharmaceutical companies, whose leading position in cancer...

  • GSK revenue disappoints with 3% fall to $8.9B Wednesday, 22 Oct 2014 | 7:22 AM ET

    GlaxoSmithKline (GSK) reported third-quarter revenue lower than analysts forecast, as sales of blockbuster asthma drug Advair continued to fall.

  • FDA panel unanimously backs Novartis' psoriasis drug Monday, 20 Oct 2014 | 2:28 PM ET

    Oct 20- An advisory panel to the U.S. Food and Drug Administration unanimously recommended the use of Novartis AG's anti-inflammation drug in patients with a type of psoriasis, paving the way for its approval. FDA staff reviewers last week had said the drug's benefits outweighed its risk. The FDA is not obligated to accept the panel's recommendations, but...

  • Ship bound TX hospital worker negative for Ebola Sunday, 19 Oct 2014 | 9:56 AM ET
    In this handout from the Center for Disease Control, a colorized transmission electron micrograph (TEM) of a Ebola virus virion is seen.

    A Dallas hospital lab worker in isolation on a cruse after possible exposure to Ebola has tested negative for the disease.

  • US asks labs to plan to produce Ebola drug Zmapp Friday, 17 Oct 2014 | 2:32 PM ET
    In this handout from the Center for Disease Control, a colorized transmission electron micrograph (TEM) of a Ebola virus virion is seen.

    U.S. officials have asked three advanced biology laboratories to submit plans for producing the experimental Ebola drug ZMapp.

  • Oct 16- The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said. There were no major safety issues associated with secukinumab, according to the review posted on the FDA website on Thursday- four days before a panel of outside advisers is...

  • Oct 16- The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said. While the FDA is not obligated to accept the recommendations of the panel, it typically does so. The FDA staff based its recommendation on the review of the data from this study,...

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug. Israel- based Teva is battling to protect a key patent for the $4- billion- a-year MS drug that is...

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug. The $4- billion- a-year drug accounts for 50 percent of Teva profits, and the patent fight is one...

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's...

  • Oct 8- Amgen Inc said its copycat version of AbbVie Inc's blockbuster biotech drug Humira showed comparable safety and ability to generate immune response in patients with a type of skin disease. "We remain bullish about AMGN's biosimilar prospects given the manufacturing expertise which would likely be key for success in biosimilar competition," Deutsche...

  • GSK investigating corruption allegations in UAE Wednesday, 8 Oct 2014 | 1:17 AM ET

    GlaxoSmithKline, which was slapped with a record fine for corruption in China, said it was looking into allegations of corruption in UAE.

  • *GSK says UAE investigations part of wider Middle East probe. LONDON, Oct 7- Drugmaker GlaxoSmithKline, which was slapped with a record $489 million fine for corruption in China last month, said on Tuesday it was looking into allegations of corruption in the United Arab Emirates. The company is already investigating alleged bribery in a number of Middle East...

  • Oct 3- The U.S. Supreme Court's new term is due to begin on Monday. *Texas Department of Housing and Community Affairs v. In July 2013, the appeals court ruled in favor of two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta Pharmaceuticals Inc and another involving Mylan Inc and Natco Pharma Ltd..